CFO
DXCM icon

Callan Family Office’s DexCom DXCM Stock Holding History

Callan Family Office’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$380K Sell
6,050
-7,491
-55% -$522K 0.01% 855
2025
Q4 		$899K Sell
13,541
-8,088
-37% -$523K 0.02% 579
2025
Q3 		$1.46M Sell
21,629
-2,203
-9% -$174K 0.05% 316
2025
Q2 		$2.08M Buy
23,832
+16,443
+223% +$1.29M 0.07% 267
2025
Q1 		$505K Buy
7,389
+4,328
+141% +$353K 0.04% 318
2024
Q4 		$238K Buy
+3,061
New +$227K 0.02% 558

Other funds holding DXCM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Callan Family Office's DXCM Position: Q1 2026 in Review

Callan Family Office reduced its DexCom (DXCM) stake by 55% in Q1 2026, selling an estimated $522K and leaving 6,050 shares worth $380K. The position accounts for 0.01% of the portfolio, ranked #855.

Callan Family Office first reported a position in DXCM in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.08M in Q2 2025. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Callan Family Office held 6,050 shares of DexCom worth $380K as of Q1 2026.
  • Callan Family Office sold 7,491 DexCom shares in Q1 2026, an estimated $522K.
  • DexCom made up 0.01% of Callan Family Office's portfolio in Q1 2026, its #855 holding.
  • Callan Family Office first reported a position in DexCom in Q4 2024 and has held it in 6 quarters since.
  • Callan Family Office's DexCom position peaked at $2.08M in Q2 2025.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.